drugset / Trial / NCT05340270
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Phase 2
Active not recruiting
150 enrolled
Guangxi Medical University
Affiliated Hospital of North Sichuan Medical College · collabFirst People's Hospital of Yulin · collabFourth Affiliated Hospital of Guangxi Medical University · collabGuigang People's Hospital · collabHainan People's Hospital · collabLiuZhou People's Hospital · collabWuzhou Red Cross Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma.
Timeline
- Start
- 2022-07-15
- Primary completion
- 2026-03-29
- Completion
- 2029-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |